Home > Back to Publisher > Report Information

Monoclonal Therapeutics and Companion Diagnostic Products

BCC Research
January 1, 2008
SKU: WA1687243

Abstract Table of Contents Related Reports

BCC's goal in conducting this study was to determine the current status of the global therapeutic and diagnostic markets for monoclonal antibodies and their growth potential over a 5 year period from 2007 to 2012. We were particularly interested in the position of the antibody market in the immediate future compared to how it has performed in the recent past as well as how the market compares to that of small molecule pharmaceuticals.

Our key objective was to present a comprehensive analysis of the current monoclonal antibody market and its future direction.

INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THIS STUDY; SCOPE OF REPORT; INTENDED AUDIENCE; METHODOLOGY; INFORMATION SOURCES; ABOUT THE AUTHOR; RELATED BCC WORK CREDENTIALS; BCC ONLINE SERVICES; DISCLAIMER
EXECUTIVE SUMMARY: MAB GROWTH IN THERAPEUTICS; PHARMA MOVES IN; MAB GROWTH IN DIAGNOSTICS; KEY DRIVERS AND CHALLENGES; SIGNIFICANT TRENDS
OVERVIEW: OVERVIEWC(CONTINUED); MAB TECHNOLOGY: BEGINNINGS AND MOVEMENTS; MOVING TOWARDS HUMANIZATION; ANTIBODY TECHNOLOGY TYPES; HUMANIZATION; SUPERHUMANIZATION; SMART TECHNOLOGY; EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%); FULLY HUMAN TECHNOLOGY; PHAGE DISPLAY; Phage Display (Continued); CRUCELL’S PER.C6 AND MABSTRACT; TRANSGENIC MICE; EMERGING ANTIBODY TECHNOLOGY TYPES; Fragments; Single Chain Antibodies; Bispecific Antibodies; Conjugation; TECHNOLOGY RELATED ISSUES AND CHALLENGES; Optimization; Adjusting Glycosylation; MANUFACTURING; LEGALITY AND INTELLECTUAL PROPERTY; Legality and Intellectual Property (Continued); PHARMACEUTICAL AND BIOTECHNOLOGY LANDSCAPE; Pharmaceutical and Biotechnology … (Continued)
MABS IN THERAPEUTICS: SIGNIFICANT TRENDS; EXPANDING INDICATIONS; NOVEL MECHANISMS OF ACTION; NOVEL APPLICATIONS; GROUPS OR COMBINATIONS OF ANTIBODIES AND; OTHER AGENTS; FRAGMENTS OF ANTIBODIES (FABS); COMPANION DIAGNOSTICS; MARKETS FOR THERAPEUTIC MABS COMPARED; THERAPEUTIC AREAS DETAILED; ONCOLOGY; Oncology (Continued); ONCOLOGY MARKET AS A WHOLE; AIID; RESPIRATORY; TRANSPLANTATION; CENTRAL NERVOUS SYSTEM (CNS); CARDIOVASCULAR (CV); INFECTIOUS DISEASE; OPHTHALMOLOGY; BLOOD DISORDERS; WOMEN’S HEALTH/OSTEOPOROSIS; FREQUENT MAB THERAPEUTIC TARGETS; THERAPEUTIC MABS IN THE PIPELINE
MABS IN DIAGNOSTICS: MABS IN DIAGNOSTICS; KEY DRIVERS; MABS IN DIAGNOSTIC RADIOPHARMACEUTICALS; MAbs in Diagnostic Radiopharmaceuticals (Continued); CHALLENGES FOR MAB DIAGNOSTIC; RADIOPHARMACEUTICALS; MARKET STATUS; FUTURE GROWTH EXPECTED; PATHWAYS FORWARD; MABS IN IMMUNOASSAYS; IHC AND COMPANION DIAGNOSTICS; COMPANY MOVEMENTS; Company Movements (Continued); REGULATORY PATHMAKING; EMERGING COMPANION DIAGNOSTIC PRESENCE; A NEW PARADIGM: MULTIFUNCTIONAL MABS IN DEVELOPMENT
COMPANY PROFILES: ABGENIX, INC. (NOW AMGEN); ABBOTT LABORATORIES; AERES BIOMEDICAL, LTD; ALEXION PHARMACEUTICALS, INC.; ALEXION PHARMACEUTICALS, INC. (CONTINUED); AMGEN, INC.; ARIUS RESEARCH, INC.; ASTRAZENECA; BECKMAN COULTER; BIOGEN IDEC, INC.; BIOGEN IDEC, INC. (CONTINUED); BIOGEN IDEC, INC. (CONTINUED); CAMBRIDGE ANTIBODY TECHNOLOGY, LTD; CENTOCOR; CHUGAI PHARMACEUTICAL; CRUCELL; CURAGEN CORPORATION; CYTOGEN CORPORATION; DYAX CORPORATION; ELAN CORPORATION; ELAN CORPORATION (CONTINUED); EISAI CO., LTD.; GENENTECH, INC.; GENENTECH, INC. (CONTINUD); GENMAB A/S; GENZYME CORPORATION; GLAXOSMITHKLINE, PLC; GLAXOSMITHKLINE, PLC (CONTINUD); IMCLONE SYSTEMS; IMMUNOGEN; IMMUNOMEDICS, INC; LONZA BIOLOGICS; MEDAREX, INC.; MERCK SERONO; MICROMET; MILLENNIUM PHARMACEUTICALS, INC; MORPHOSYS AG; NABI PHARMACEUTICALS; NOVARTIS PHARMACEUTICALS CORPORATION; ORTHO BIOTECH PRODUCTS; ONYVAX; PDL BIOPHARMA; PROGENICS PHARMACEUTICALS; REGENERON PHARMACEUTICALS, INC.; ROCHE; SEATTLE GENETICS; TANABE SEIYAKU CO., LTD; UCB S.A.; VIVALIS; VIVENTIA BIOTECH, INC; WYETH PHARMACEUTICALS, INC.; XOMA, LTD
LIST OF TABLES: SUMMARY TABLE WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC AND COMPANION DIAGNOSTICS, THROUGH 2012 ($ BILLIONS); TABLE 1 BIOPHARMACEUTICAL CATEGORIES; TABLE 2 MONOCLONAL ANTIBODIES APPROVED FOR DISEASE THERAPY*; TABLE 3 TIMELINE FOR MAB DEVELOPMENT; TABLE 4 WORLDWIDE FORECAST OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY TYPE, THROUGH 2012 ($ BILLIONS); TABLE 5 SMART TECHNOLOGY ROYALTIES BY LICENSEE AND PRODUCT AS A PERCENTAGE OF TOTAL ROYALTY REVENUE: EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%); TABLE 6 TRANSGENIC TECHNOLOGIES; TABLE 7 LEADING CONJUGATION TECHNOLOGIES; TABLE 8 ANTIBODY TECHNOLOGY BEHIND COMMERCIALIZED MABS; TABLE 9 CAT’S PHAGE AND RIBOSOME DISPLAY PATENTS; TABLE 10 PHARMA’S MAB-RELATED ACQUISITIONS; TABLE 11 GLOBAL SNAPSHOT: BIOTECHNOLOGY INDUSTRY*; TABLE 12 MARKET VALUE OF BIOPHARMACEUTICAL THERAPEUTIC AREAS, THROUGH 2012 ($ BILLIONS); TABLE 13 WORLDWIDE SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY THERAPEUTIC AREA, THROUGH 2012 ($ BILLIONS); TABLE 14 GROWTH OF COMMERCIALIZED MONOCLONAL ANTIBODIES BY THERAPEUTIC AREA, THROUGH 2012 (NUMBER OF COMMERCIALIZED ANTIBODIES EACH YEAR); TABLE 15 BIOPHARMACEUTICAL MARKET VALUE OF VARIOUS DISEASES/CONDITIONS, THROUGH 2012 ($ BILLIONS); TABLE 16 CANCER’S GLOBAL ANNUAL DEATH TOLL; TABLE 17 ESTIMATED NEW CASES OF CANCER IN THE U.S., 2007; TABLE 18 CNS GLOBAL MARKET VALUES ($ BILLIONS); TABLE 19 COMMON ANTIGEN TARGETS EXPLAINED; TABLE 20 THERAPEUTIC PIPELINE: SELECTED MABS IN DEVELOPMENT; TABLE 21 WORLDWIDE VALUE OF MAB-ASSOCIATED DIAGNOSTICS, BY TECHNOLOGY TYPE, THROUGH 2012 ($ BILLIONS); TABLE 22 SCANNING TECHNOLOGIES THAT ARE USED WITH DIAGNOSTIC RADIOPHARMACEUTICALS; TABLE 23 MAB-BASED DIAGNOSTIC RADIOPHARMACEUTICALS: CURRENT AND EMERGING; TABLE 24 A NEW PARADIGM: MULTIFUNCTIONAL MAB DEVELOPMENT PIPELINE; TABLE 25 ABBOTT PRODUCT CATEGORIES; TABLE 26 HUMIRA’S LIFECYCLE TO DATE; TABLE 27 AMGEN’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT; TABLE 28 ASTRAZENECA’S KEY BIOLOGICALS IN CLINICAL TRIALS; TABLE 29 ASTRAZENECA’S KEY BIOLOGICALS IN PRECLINICALS; TABLE 30 CHUGAI’S ANTIBODY-BASED PIPELINE; TABLE 31 CURAGEN’S ANTIBODY-BASED DRUG CANDIDATES; TABLE 32 EISAI’S (MORPHOTECK ACQUISITION) MONOCLONAL PIPELINE; TABLE 33 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES; TABLE 34 SELECTED ADDITIONAL PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES; TABLE 35 IMMUNOMEDICS’ THERAPEUTIC PRODUCT PIPELINE; TABLE 36 MEDAREX’S PRODUCT PIPELINE; TABLE 37 MICROMET’S PIPELINE; TABLE 38 MILLENNIUM’S PRODUCTS IN PHASE II OR LATER DEVELOPMENT; TABLE 39 MORPHOSYS HUCAL-BASED ANTIBODY PRODUCTS; TABLE 40 MORPHOSYS’ PATENT PORTFOLIO; TABLE 41 PDL BIOPHARMA’S PRODUCTS IN PHASE II OR LATER; TABLE 42 TANABE SEIYAKU’S ANTIBODY-BASED PIPELINE
LIST OF FIGURES: SUMMARY FIGURE WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC AND COMPANION DIAGNOSTICS, 2005-2012 ($ BILLIONS); FIGURE 1 COMPOSITION OF COMMERCIALIZED ANTIBODIES BY TYPE, 2007 AND 2012 (%); FIGURE 2 ANTIBODY ILLUSTRATED; FIGURE 3 THE SYNERGY OF PHARMA AND BIOTECH; FIGURE 4 SHARE OF MONOCLONAL ANTIBODY THERAPY MARKET BY THERAPEUTIC AREA, 2007 AND 2012 (%); FIGURE 5 MAJOR MAB ANTIGEN TARGETS COMMERCIALIZED; FIGURE 6 WORLDWIDE IN-VITRO DIAGNOSTIC MARKET SHARE BY THERAPEUTIC AREA, 2006 (%)

Monoclonal Therapeutics and Companion Diagnostic Products

Share this report

Other tasks

Research Assistance

Related Markets

Companion Diagnostics Reports

Free Alert Me service